Search results
PROMOTED
How do worsening heart events dictate the long-term outcomes of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and can earlier intervention influence the disease trajectory in ATTR-CM? In this new sub-analysis from ATTRibute-CM, recorded onsite at ESC Heart Failure Congress (HFA) 2026, Prof Marianna Fontana (University College London, London, UK) sheds further light onto these…
View more
HFA 2026: Updates on ATTR-CM
Added:
1 month ago
Video Series
Added:
1 year ago
Added:
7 months ago
AHA Scientific Sessions 2025 – MAPLE-HCM responder analysis shows aficamten monotherapy led to greater treatment effect when compared to metoprolol monotherapy.Dr Andrew Wang (Duke University Medical Center, Durham, NC, US) presents a responder analysis from the MAPLE-HCM trial (NCT05767346), examining clinical responses to aficamten monotherapy versus metoprolol in patients with obstructive…
View more
Meta-analysis and Meta-regression Applicability
Added:
8 months ago
Review Article
Added:
1 year ago
ESC HF 25 - Secondary analysis of the FINEARTS-HF study shows finerenone treatment favourably influenced the risk of early heart failure readmission.Dr Ankeet Bhatt (Kaiser Permanante San Francisco Medical Center, San Francisco, US) discusses findings from the prespecified secondary analysis of the FINEARTS-HF trial (NCT04435626; Bayer). The placebo-controlled primary analysis investigated the…
View more
Added:
1 year ago
EuroPCR 25 - A meta-analysis of the individual patient data from the PROTECTED TAVR and BHF PROTECT-TAVI studies show TAVI with cerebral embolic protection (CEP) may reduce the rate of disabling stroke compared to TAVI without CEP.We are joined by Prof Rajesh Kharbanda (Oxford Radcliffe Hospitals NHS Trust, Oxford, UK) to discuss outcomes from a meta-analysis investigating TAVI with or without…
View more
Added:
1 year ago
EuroPCR 25 - Post-hoc anlysis outcomes from under-expansion of the ACURATE neo2 valve in severe aortic stenosis (AS) patients show under-expansion was associated with higher rates of death, stroke or rehospitalisation.We are joined by Dr Raj Makkar (Cedars-Sinai Heart Institute, Los Angeles, US) to discuss findings from the post-hoc analysis of the ACURATE IDE study (NCT03735667; Boston…
View more
Added:
1 year ago
ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in…
View more
Added:
2 years ago
HFA 24 - We are joined by Dr Jasper J Brugts (Erasmus University Medical Centre, NL) to discuss the findings of a predefined subgroup analysis of the MONITOR-HF study (NTR7672).MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation,…
View more
Added:
9 months ago
ESC Congress 2025 - Vericiguat significantly reduced risks of CV mortality and HF hospitalisations, as well as all-cause mortality across both the VICTOR and VICTORIA Trial.Dr JavedButler (Baylor Scott & White Health, Dallas, US) joins us to discuss findings from a pooled analysis of the recent VICTOR and VICTORIA trials, with data from 11155 participants with heart failure with reduced ejection…
View more